Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Methyldopa. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 1.00 |
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | BLM | P54132 | 4/20 | 1.00 |
| ▸ | HPGD | P15428 | 4/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 4/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 1.00 |
| ▸ | POLB | P06746 | 3/20 | 1.00 |
| ▸ | APEX1 | P27695 | 3/20 | 1.00 |
| ▸ | RECQL | P46063 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | GAA | P10253 | 2/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 2/20 | 1.00 |
| ▸ | USP2 | O75604 | 2/20 | 1.00 |
| ▸ | EGFR | P00533 | 2/20 | 1.00 |
| ▸ | FYN | P06241 | 2/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methyldopa SCHEMBL30176814 | 1.00 | KDM4E (1.00) | KDM4EHSD17B10TDP1MAPTBLM | |
| Methyldopa (Racemic) SCHEMBL196981 | 1.00 | KDM4E (1.00) | KDM4EHSD17B10TDP1MAPTBLM | |
| Methyldopa SCHEMBL1321546 | 1.00 | KDM4E (1.00) | KDM4EHSD17B10TDP1MAPTBLM | |
| Methyldopa SCHEMBL34003 | 1.00 | KDM4E (1.00) | KDM4EHSD17B10TDP1MAPTBLM | |
| Methyldopa SCHEMBL1172822 | 1.00 | KDM4E (1.00) | KDM4EHSD17B10TDP1MAPTBLM | |
| Methyldopa (Racemic) SCHEMBL29013197 | 0.98 | KDM4E (0.97) | KDM4EHSD17B10TDP1MAPTBLM | |
| Methyldopa (Racemic) SCHEMBL259452 | 0.98 | KDM4E (0.97) | KDM4EHSD17B10TDP1MAPTBLM | |
| Methyldopa (Racemic) SCHEMBL5929436 | 0.98 | KDM4E (0.97) | KDM4EHSD17B10TDP1MAPTBLM | |
| Methyldopa SCHEMBL5370162 | 0.98 | KDM4E (0.97) | KDM4EHSD17B10TDP1MAPTBLM | |
| Methyldopa SCHEMBL11452341 | 0.98 | KDM4E (0.97) | KDM4EHSD17B10TDP1MAPTBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 158 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12251368-B2 | Continuous administration of pharmaceutical composition for treatment of neurodegenerative disorders | INTRANCE MEDICAL SYSTEMS INC. (US) | 2025-03-18 | — | — | US | claimed |
| US-20250041257-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING LEVODOPA, A DOPAMINE DECARBOXYLASE INHIBITOR AND A COMT INHIBITOR AND METHOD OF ADMINISTRATION THEREOF | INTRANCE MEDICAL SYSTEMS INC. | 2025-02-06 | — | — | US | claimed |
| CN-118121710-A | Continuous administration of pharmaceutical compositions for the treatment of neurodegenerative diseases | 劳波索尔制药有限公司 | 2024-06-04 | — | — | CN | claimed |
| CN-112261940-B | Continuous administration of pharmaceutical compositions for the treatment of neurodegenerative diseases | 劳波索尔制药有限公司 | 2024-02-27 | — | — | CN | claimed |
| CN-109988312-B | Polyamide acid ester, preparation method, negative polyimide composition and application | 深圳先进技术研究院 | 2023-04-11 | — | — | CN | claimed |
| CN-113963798-A | Parkinson's disease motor symptom evaluation method | 华中科技大学同济医学院附属协和医院 | 2022-01-21 | — | — | CN | claimed |
| WO-2026089754-A1 | COMPOSITIONS AND METHODS FOR INTRANASAL DELIVERY OF THERAPEUTIC PEPTIDES | Finitus, LLC (US) | 2026-04-30 | — | — | WO | disclosed |
| WO-2026089753-A1 | COMPOSITIONS AND METHODS FOR INTRANASAL DELIVERY OF CARNOSINE FOR TREATMENT OF NEURODEGENERATIVE DISEASES AND DISORDERS | Finitus, LLC (US) | 2026-04-30 | — | — | WO | disclosed |
| US-20260116885-A1 | ION CHANNEL MODULATORS | PRAXIS PREC MEDICINES INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260108583-A1 | COMPOSITIONS AND METHODS FOR INTRANASAL DELIVERY OF THERAPEUTIC PEPTIDES | FINITUS LLC (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260108582-A1 | COMPOSITIONS AND METHODS FOR INTRANASAL DELIVERY OF CARNOSINE FOR TREATMENT OF NEURODEGENERATIVE DISEASES AND DISORDERS | FINITUS LLC (US) | 2026-04-23 | — | — | US | disclosed |
| US-12605384-B2 | Uses | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| EP-3746081-B1 | PDE1 INHIBITORS FOR USE TO TREAT CARDIAC FAILURE AND CARDIOTOXICITY | INTRA CELLULAR THERAPIES INC (US) | 2026-04-01 | — | — | EP | disclosed |
| CN-114159417-A | Compound medicine for treating Parkinson's disease and preparation method thereof | 杭州泓友医药科技有限公司 | 2022-03-11 | — | — | CN | disclosed |
| US-11260127-B2 | Mesoporous silica nanoparticles for diagnostic and therapeutic applications | CASE WESTERN RESERVE UNIVERSITY (US) | 2022-03-01 | — | — | US | disclosed |
| US-20220054433-A1 | AGENTS FOR REVERSING TOXIC PROTEINOPATHIES | THE BROAD INSTITUTE, INC. (US) | 2022-02-24 | — | — | US | disclosed |
| US-20220049306-A1 | CARDIOVASCULAR DISEASE | GENINCODE UK, LTD. (GB) | 2022-02-17 | — | — | US | disclosed |
| US-20220024930-A1 | ION CHANNEL MODULATORS | PRAXIS PRECISION MEDICINES, INC. | 2022-01-27 | — | — | US | disclosed |
| US-20220023233-A1 | AGENTS FOR REVERSING TOXIC PROTEINOPATHIES | THE BROAD INSTITUTE, INC. (US) | 2022-01-27 | — | — | US | disclosed |
| CN-113963798-A | Parkinson's disease motor symptom evaluation method | 华中科技大学同济医学院附属协和医院 | 2022-01-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260108582-A1 | COMPOSITIONS AND METHODS FOR INTRANASAL DELIVERY OF CARNOSINE FOR TREATMENT OF NEURODEGENERATIVE DISEASES AND DISORDERS | SNCA, CLN6, PRNP | ADRA2A 361/4885KDM4E 3085/4885HSD17B10 2648/4885 |
| US-20220024930-A1 | ION CHANNEL MODULATORS | SCN1A, SCN3A, SCN2A | ADRA2A 876/4885KDM4E 2324/4885HSD17B10 1136/4885 |
| US-12251368-B2 | Continuous administration of pharmaceutical composition for treatment of neurodegenerative disorders | COMT, DBH, DDC | ADRA2A 457/4885KDM4E 3114/4885HSD17B10 628/4885 |
| US-20260108583-A1 | COMPOSITIONS AND METHODS FOR INTRANASAL DELIVERY OF THERAPEUTIC PEPTIDES | MUC1, VIP, LGALS4 | ADRA2A 375/4885KDM4E 2677/4885HSD17B10 2811/4885 |
| US-20260116885-A1 | ION CHANNEL MODULATORS | SCN1B, SCN1A, CACNA1S | ADRA2A 556/4885KDM4E 3535/4885HSD17B10 1519/4885 |
| US-20220054433-A1 | AGENTS FOR REVERSING TOXIC PROTEINOPATHIES | MUC1, TMIGD3, TMED9 | ADRA2A 3755/4885KDM4E 3456/4885HSD17B10 3826/4885 |
| US-12605384-B2 | Uses | PDE2A, NPR1, PDE7A | ADRA2A 21/4885KDM4E 3738/4885HSD17B10 3035/4885 |
| US-20250041257-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING LEVODOPA, A DOPAMINE DECARBOXYLASE INHIBITOR AND A COMT INHIBITOR AND METHOD OF ADMINISTRATION THEREOF | COMT, DDT, DDC | ADRA2A 551/4885KDM4E 2245/4885HSD17B10 431/4885 |
| US-20220023233-A1 | AGENTS FOR REVERSING TOXIC PROTEINOPATHIES | MUC1, TMIGD3, TMED9 | ADRA2A 3755/4885KDM4E 3456/4885HSD17B10 3826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.